Similar articles

• No D2 receptor increase in PET study of schizophrenia.

  Farde L, Wiesel FA, Hall H, Halldin C, Stone-Elander S, Sedvall G. Farde L, et al. Arch Gen Psychiatry. 1987 Jul;44(7):671-2. doi: 10.1001/archpsyc.1987.01800190091013. Arch Gen Psychiatry. 1987. PMID: 2955770 No abstract available.
• D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

  Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, Sedvall G. Farde L, et al. Arch Gen Psychiatry. 1990 Mar;47(3):213-9. doi: 10.1001/archpsyc.1990.01810150013003. Arch Gen Psychiatry. 1990. PMID: 1968328
• Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.

  Seeman P, Niznik HB, Guan HC. Seeman P, et al. Arch Gen Psychiatry. 1990 Dec;47(12):1170-2. doi: 10.1001/archpsyc.1990.01810240090014. Arch Gen Psychiatry. 1990. PMID: 2244801 No abstract available.
• Raclopride, a new selective ligand for the dopamine-D2 receptors.

  Hall H, Köhler C, Gawell L, Farde L, Sedvall G. Hall H, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):559-68. doi: 10.1016/0278-5846(88)90001-2. Prog Neuropsychopharmacol Biol Psychiatry. 1988. PMID: 2975809 Review.
• The current status of PET scanning with respect to schizophrenia.

  Sedvall G. Sedvall G. Neuropsychopharmacology. 1992 Aug;7(1):41-54. Neuropsychopharmacology. 1992. PMID: 1388021 Review.